Beyond Biotech - the podcast from Labiotech

Could antigen modulation address autoimmune diseases?


Listen Later

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.

However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle.

To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances the immune response​. The final step is cytokine-mediated differentiation and expansion, which guides how T-cells target threats. ​

Companies have focused on the second two signals, with signal 2 most commonly seen in therapies such as checkpoint inhibitors and monoclonal antibodies. Signal 3, on the other hand, can be primarily seen in therapies for autoimmune disorders, such as anti-TNF and JAK inhibitors.

Greywolf Therapeutics is the first company to explore changing signal 1. The company says focusing on signal 1 applies in three key therapeutic areas: oncology, autoimmunity and virology. 

Greywolf’s first candidate has delivered strong results during its ongoing phase I/II trial in oncology, therefore demonstrating proof-of-mechanism and target engagement, with its next candidate well-progressed in preclinical development in autoimmunity.

To tell us more about the company and its work is Pete Joyce, CEO and co-founder of Greywolf Therapeutics.

01:19-04:12: About Greywolf Therapeutics
04:12-04:51: The origins of the name
04:51-06:52: The three ‘signals’ of the mechanics of immunological responses
06:52-08:31: Treatments associated with each signal
08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments?
10:09-11:28: What areas of disease is this applicable to?
11:28-12:19: How do you inhibit ERAP?
12:19-14:01: Greywolf Therapeutics’ candidates
14:01-15:11: How is this an advance on current treatments?
15:11-16:05: What is success for patients?
16:05-17:20: How does the stage of disease affect treatment?
17:20-18:09: Are other companies looking into antigen modulation? 
18:09-19:47: Has this led to investment opportunities?
19:47-21:15: Next steps
21:15-21:55: Do you anticipate more interest in this space?
21:55-23:21: Attending events 

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter


...more
View all episodesView all episodes
Download on the App Store

Beyond Biotech - the podcast from LabiotechBy Labiotech

  • 3.3
  • 3.3
  • 3.3
  • 3.3
  • 3.3

3.3

3 ratings


More shows like Beyond Biotech - the podcast from Labiotech

View all
Fareed Zakaria GPS by CNN

Fareed Zakaria GPS

3,443 Listeners

Making Sense with Sam Harris by Sam Harris

Making Sense with Sam Harris

26,420 Listeners

The Bio Report by Levine Media Group

The Bio Report

39 Listeners

The Daily by The New York Times

The Daily

111,441 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

The Readout Loud by STAT

The Readout Loud

317 Listeners

Biotech 2050 Podcast by Biotech 2050

Biotech 2050 Podcast

59 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

87 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

29 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

147 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,216 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

10 Listeners

The Foreign Affairs Interview by Foreign Affairs Magazine

The Foreign Affairs Interview

412 Listeners

Ground Truths by Eric Topol

Ground Truths

47 Listeners

The Wirecutter Show by The New York Times

The Wirecutter Show

1,071 Listeners